- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT06272981
Tutkimus THERMOCOOL SMARTTOUCH Surround Flow (SF) -katetrista TRUPULSE-generaattorilla lääkkeitä kestävien oireiden aiheuttaman PAFOUSin hoitoon (PulseSmart)
THERMOCOOL SMARTTOUCH™ SF -katetrin turvallisuuden ja tehokkuuden arviointi TRUPULSE™-generaattorilla lääkkeitä kestävien oireiden aiheuttaman paroksysmaalisen eteisvärinän (PAF) hoitoon
The purpose of this study is to demonstrate safety and effectiveness of the Biosense Webster (BWI) ablation system (THERMOCOOL SMARTTOUCH surround flow [STSF] catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF), an irregular heart rate that causing abnormal blood flow.
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Camperdown, Australia, 2050
- Royal Prince Alfred Hospital
-
Garran, Australia, 2605
- Canberra Heart Rhythm
-
Westmead, Australia, 2145
- Westmead Hospital
-
-
-
-
Ontario
-
Newmarket, Ontario, Kanada, L3Y 2P9
- Southlake Regional Health Centre
-
Ottawa, Ontario, Kanada, K1Y 4W7
- University of Ottawa Heart Institute
-
-
Quebec
-
Montreal, Quebec, Kanada, H3G 1A4
- McGill University Health Centre
-
Montreal, Quebec, Kanada, H1T 1C8
- Montreal Heart Institute
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria::
- Diagnosed with Symptomatic PAF (Physician's note indicating recurrent self-terminating AF). At least one (1) electrocardiographically documented AF episode within twelve (12) months prior to enrollment. Electrocardiographic documentation may include, but is not limited to, electrocardiogram (ECG), Holter monitor, or other electrocardiographical devices accepted by investigators
- Failed at least one (1) Class I or Class III Antiarrhythmic Drug (AAD) as evidenced by recurrent symptomatic AF or has intolerable side effects or is contraindicated to the Class I or Class III AAD
- Able and willing to comply with all pre-procedure, post-procedure, and follow-up testing and visit requirements
- Willing and capable of providing consent
Exclusion Criteria:
- AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause (e.g., untreated documented obstructive sleep apnea and acute alcohol toxicity)
- Previous LA ablation or surgery
- Patients known to require ablation outside the PV region (atrioventricular reentrant tachycardia, atrioventricular nodal reentry tachycardia, atrial tachycardia, atrial flutter of unknown origin, ventricular tachycardia and Wolff-Parkinson-White)
- Previously diagnosed with persistent AF (> 7 days in duration)
- Severe dilatation of the LA (documented LAD >50mm antero-posterior diameter on imaging within 6 months prior to enrollment
- Documented left atrium (LA) thrombus within 48 hours prior to the index procedure by Transesophageal Echocardiography (TEE), or by Intracardiac Echocardiography (ICE) prior to transeptal puncture during procedure
- Documented severely compromised LVEF (LVEF <40%) by imaging within 6 months prior to enrollment
- Uncontrolled heart failure or New York Heart Association (NYHA) Class III or IV
- History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran)
- History of a documented thromboembolic event (including TIA) within the past 12 months, or history of a documented left atrial appendage (LAA) thrombus
- History of a documented symptomatic lacunar infarction within the past 12 months
- Previous PCI/MI within the past 2 months
- Coronary Artery Bypass Grafting (CABG) surgery within past 6 months
- Valvular surgery, cardiac surgery (e.g., ventriculotomy, atriotomy) or valvular cardiac (surgical or percutaneous) procedure
- Unstable angina pectoris within the past 6 months
- Anticipated cardiac transplantation, cardiac surgery or other major surgery within the next 12 months
- Significant pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms
- Known significant PV anomaly that in the opinion of the investigator would preclude enrollment in this study
- Has known pulmonary vein stenosis
- Pre-existing hemi diaphragmatic paralysis
- Acute illness, active systemic infection or sepsis
- Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation
- Severe mitral regurgitation (Regurgitant volume 60 mL/beat, Regurgitant fraction 50%, and/or Effective regurgitant orifice area 0.40cm^2)
- Presence of implanted pacemaker, Implantable Cardioverter-Defibrillator (ICD), recently implanted (within 6 months) LAAO device or other implanted metal cardiac device within the cardiac space that may interfere with the energy field created during the ablation procedure.
- Presence of a condition that precludes vascular access (such as IVC filter)
- Significant congenital anomaly or a medical problem that in the opinion of the investigator would preclude enrollment in this study
- Categorized as vulnerable population and requires special treatment with respect to safeguards of well-being
- Current enrollment in an investigational study evaluating another device or drug
- Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of childbearing age and plan on becoming pregnant during the course of the clinical investigation
- Life expectancy less than 12 months
- History of massive hemorrhage within the past 6 months
- Presenting contra-indications for the devices
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Pulsed Field (PF)/Radiofrequency (RF) Ablation System
Participants with drug refractory symptomatic PAF who are candidates for atrial fibrillation ablation uses PF and RF energy to produce targeted intracardiac lesions for the treatment of atrial fibrillation. |
THERMOCOOL STSF catheter will be used in conjunction with TRUPULSE Generator to give PF ablation or RF ablation. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of Participants With Primary Adverse Events (PAEs)
Aikaikkuna: Up to 12 Months post ablation procedure on Day 0
|
An adverse event (AE) was any untoward medical occurrence, unintended disease or injury or any untoward clinical signs, including abnormal laboratory finding, in participants or users in context of clinical investigation, whether or not related to device/procedure. PAEs included the following adverse events: Device or procedure related death within 30 days of ablation procedure, esophageal perforating complications (atrio-esophageal fistula [up to 90 days post ablation procedure], esophago-pericardial fistula), myocardial infarction, cardiac tamponade/perforation up to 30 days post ablation, thromboembolism, stroke/cerebrovascular accident (CVA), transient ischemic attack (TIA), phrenic nerve paralysis, pulmonary vein stenosis (occurring anytime during 12 month follow-up period considered a PAE), major vascular access complication/bleeding, pericarditis, heart block, pulmonary edema (respiratory insufficiency), and vagal nerve injury/gastroparesis. |
Up to 12 Months post ablation procedure on Day 0
|
|
Percentage of Participants With Freedom From Documented (Symptomatic and Asymptomatic) Atrial Arrhythmia (Atrial Fibrillation [AF], Atrial Tachycardia [AT] or Atrial Flutter [AFL]) Episodes Based on Electrocardiographic Data and From All Failure Modes
Aikaikkuna: From Day 91 up to Day 365 post ablation procedure on Day 0
|
Percentage of participants with freedom from documented (symptomatic and asymptomatic) atrial arrhythmia (AF, AT or AFL) episodes based on electrocardiographic data and from all failure modes were reported. Atrial tachyarrhythmia (AF/AT/AFL of unknown origin) episodes were based on electrocardiographic data [12-lead electrocardiogram(ECG) or greater than or equal to(>=) 30 seconds on ECG or sponsor provided transtelephonic monitor (TTM) or Holter device] during effectiveness evaluation period (Day 91 to Day 365) and any of following failure modes: acute procedural, repeat ablation, non-study device, anti-arrhythmic drug (AAD), continuous AF/AT/AFL of unknown origin, and any direct current cardioversion procedure during evaluation period for documented atrial tachyarrhythmia (AF/AT/AFL of unknown origin). AFL of unknown origin was defined as all AFL except those cavotricuspid isthmus dependent AFL as confirmed by 12-Lead ECG and entrainment maneuvers in an electrophysiology (EP) study. |
From Day 91 up to Day 365 post ablation procedure on Day 0
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change From Baseline in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score at Month 12
Aikaikkuna: Baseline, Month 12
|
Change from baseline in AFEQT total score at Month 12 was reported. AFEQT questionnaire was used to assess the quality-of-life post ablation procedure. The AFEQT questionnaire included 20 questions on a 7-point Likert scale. Questions 1-18 evaluated health-related quality of life (HRQoL), including AF-related symptoms (Questions 1-4), daily activities (Questions 5-12), and treatment concerns (Questions 13-18), while Questions 19-20 assessed participant satisfaction with treatment. The first 18 questions were used to calculate the overall AFEQT scores. Scores are transformed to a scale ranging from 0 to 100, where a score of 0 indicated complete disability and a score of 100 indicated no disability. Higher scores indicated improvement. The formula to calculate these scores is as follows: 100 minus([sum of severity for all questions answered minus number of questions answered]*100 divided by total number questions answered*6). |
Baseline, Month 12
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Biosense Webster, Inc. Clinical Trial, Biosense Webster, Inc.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- BWI202308
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .